Ramy Abdelnaby: Exploring Advances in Antithrombotic Therapy for Noncardioembolic Ischemic Stroke
Ramy Abdelnaby, Consultant Neurologist / Oberarzt at RWTH Aachen University Hospital, shared on LinkedIn about a recent article by Brett Cucchiara et al, published in Stroke:
”Exploring advances in antithrombotic therapy for noncardioembolic ischemic stroke: The OCEANIC-STROKE trial marks a significant development with its dual-pathway inhibition approach using asundexian alongside antiplatelet therapy.
Current evidence highlights the efficacy of antiplatelet monotherapy and, in certain scenarios, the superiority of dual-antiplatelet therapy shortly after an event.
However, the emerging promise of factor XI/XIa inhibitors could revolutionize secondary stroke prevention, potentially enhancing efficacy without increasing bleeding risks.
Dive into the latest findings and what they signify for future treatment directions.”
Title: Antithrombotic Therapy for Noncardioembolic Ischemic Stroke: Current Evidence and Future Directions
Authors: Brett Cucchiara, Jean M. Connors, Alejandro A. Rabinstein, Mukul Sharma
Read the Full Article on Stroke
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS